Adrian Oblak, Ph.D.

Research Assistant Professor, Radiology & Imaging Sciences
Project Manager, IU/JAX Alzheimer Disease Modeling Project  


PhD, Anatomy & Neurobiology, Boston University School of Medicine (2010)
Post-Doc, Neurobiology, Boston Unviersity School of Medicine (2012) 

IU/Jax Alzheimer Disease Modeling Project

The Indiana University (IU)/Jackson Laboratory (JAX) Alzheimer’s Disease Precision Models Center (IU/JAX ADPMC) will leverage IU’s strengths in neurodegenerative research and considerable expertise in preclinical drug testing with JAX’s eight decades of expertise in mammalian genetics and disease modeling to develop, validate and disseminate new, precise animal models of Alzheimer’s disease (AD). In addition, the IU/JAX ADMPC contains Sage Bionetworks to provide expertise in data organization and dissemination. The IU/JAX ADPMC brings together an international, multi-disciplinary team—including geneticists and genetics technology experts, quantitative and computational biologists, clinical experts in AD and neuroimaging, pharmacologists and world leaders in the development of precision animal models of disease—that possesses the collective ability to foresee disease modeling needs as they emerge on the international stage. This will allow the IU/JAX ADPMC to serve the AD scientific community effectively and efficiently.  The IU/JAX ADPMC will generate new AD modeling processes and pipelines, data resources, research results and models that will be swiftly shared through JAX’s and Sage’s proven dissemination pipelines and through the NIA-supported AD Centers, academic medical centers, research institutions and the pharmaceutical industry worldwide. Ultimately, this will accelerate the application of advances in animal models for the greatest possible medical benefit.

Search for Dr. Oblak on PubMed


McEwan WA, Falcon B, Vaysburd M, Clift D, Oblak AL, Ghetti B, Goedert M, James LC.  Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci U S A. 2017 Jan 3. pii: 201607215. doi: 10.1073/pnas.1607215114. [Epub ahead of print]  PMID: 28049840

Galimberti D, Cioffi SM, Fenoglio C, Serpente M, Oblak AL, Rodriguez-Porcel F, Oldoni E, Hagen MC, Arcaro M, Scarpini E, Ghetti B, Espay AJ.  Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.  Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872. [Epub ahead of print] PMID: 27859661

Umeh CC, Kalakoti P, Greenberg MK, Notari S, Cohen Y, Gambetti P, Oblak AL, Ghetti B, Mari Z.  Clinicopathological Correlates in a PRNP P102L Mutation Carrier with Rapidly Progressing Parkinsonism-dystonia.  Mov Disord Clin Pract. 2016 Jul-Aug;3(4):355-358.  PMID: 27617269

Liachko NF, Saxton AD, McMillan PJ, Strovas TJ, Currey HN, Taylor LM, Wheeler JM, Oblak AL, Ghetti B, Montine TJ, Keene CD, Raskind MA, Bird TD, Kraemer BC.  The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol. 2016 Oct;132(4):545-61. doi: 10.1007/s00401-016-1600-y. PMID: 27473149

Deters KD, Risacher SL, Yoder KK, Oblak AL, Unverzagt FW, Murrell JR, Epperson F, Tallman EF, Quaid KA, Farlow MR, Saykin AJ, Ghetti B.  [(11)C]PiB PET in Gerstmann-Sträussler-Scheinker disease.  Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):84-93. PMID: 27069768

Ehrlich M, Hallmann AL, Reinhardt P, Araúzo-Bravo MJ, Korr S, Röpke A, Psathaki OE, Ehling P, Meuth SG, Oblak AL, Murrell JR, Ghetti B, Zaehres H, Schöler HR, Sterneckert J, Kuhlmann T, Hargus G.  Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein.  Stem Cell Reports. 2015 Jul 14;5(1):83-96. doi: 10.1016/j.stemcr.2015.06.001. PMID: 26143746

Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M.  Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging.  Neuropathol Appl Neurobiol. 2015 Feb;41(1):24-46. doi: 10.1111/nan.12213. Review. Erratum in: Neuropathol Appl Neurobiol. 2015 Jun;41(4):571. Neuropathol Appl Neurobiol. 2015 Jun;41(4):571. PMID: 25556536

Boyd CD, Tierney M, Wassermann EM, Spina S, Oblak AL, Ghetti B, Grafman J, Huey E.  Visuoperception test predicts pathologic diagnosis of Alzheimer disease in corticobasal syndrome.  Neurology. 2014 Aug 5;83(6):510-9. doi: 10.1212/WNL.0000000000000667. PMID: 24991033

Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B.  Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings.  Acta Neuropathol. 2014 Jul;128(1):81-98. doi: 10.1007/s00401-014-1279-x.  PMID: 24803225

Oblak A, Gibbs TT, Blatt GJ.  Reduced serotonin receptor subtypes in a limbic and a neocortical region in autism.  Autism Res. 2013 Dec;6(6):571-83. doi: 10.1002/aur.1317.  PMID: 23894004

Oblak AL, Rosene DL, Kemper TL, Bauman ML, Blatt GJ.  Altered posterior cingulate cortical cyctoarchitecture, but normal density of neurons and interneurons in the posterior cingulate cortex and fusiform gyrus in autism.  Autism Res. 2011 Jun;4(3):200-11. doi: 10.1002/aur.188.  PMID: 21360830

Oblak AL, Gibbs TT, Blatt GJ.  Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism.  Brain Res. 2011 Mar 22;1380:218-28. doi: 10.1016/j.brainres.2010.09.021.  PMID: 20858465

Oblak AL, Gibbs TT, Blatt GJ.  Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism.  J Neurochem. 2010 Sep 1;114(5):1414-23. doi: 10.1111/j.1471-4159.2010.06858.x.  PMID: 20557420

Oblak A, Gibbs TT, Blatt GJ.  Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism.  Autism Res. 2009 Aug;2(4):205-19. doi: 10.1002/aur.88. Erratum in: Autism Res. 2009 Aug;2(4):237. PMID: 19650112

Stark Neurosciences Research Institute | Neuroscience Research Building | 320 West 15th Street | Indianapolis, IN 46202 | Phone: (317) 278-5848 | FAX: (317) 231-0203